diabetes drug weight loss tirzepatide linked to more significant than semaglutide Eli Lilly's weight loss, diabetes

These include: Large disc extrusions or sequestered fragments requiring surgical intervention Severe spinal stenosis with significant canal narrowing Bone spurs (osteophytes) compressing nerve structures Advanced degenerative disc disease with complete disc height loss Spondylolisthesis (vertebral slippage) beyond grade 1 Cauda equina syndrome (medical emergency requiring immediate surgery) Users with these conditions typically report minimal improvement from peptide therapy alone

There have been no significant reports of priapism in clinical trials

Its a tri-agonist targeting three separate receptor systems simultaneously: The GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors

This pharmacokinetic profile enables weekly dosing while maintaining stable therapeutic levels throughout the dosing interval